Advanced Prostate Cancer
5,759 members5,464 posts

ProVent Trial Aims to Halt Disease Progression, Reduce Need for Prostate cancer treatment using provenge

ProVent Trial Aims to Halt Disease Progression, Reduce Need for Aggressive Intervention by provenge maker, Dendreon .

Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced it will conduct a large-scale, placebo-controlled clinical trial evaluating the effectiveness of PROVENGE® (sipuleucel-T) in reducing disease progression in men with prostate cancer.

The ProVent clinical trial will assess the efficacy of PROVENGE in reducing histopathologic disease progression in men on AS, with a targeted enrollment of 450 participants. Men age 18 or older who have histologically-proven adenocarcinoma of the prostate diagnosed within 12 months of randomization are eligible to enroll. Study enrollment is expected to begin in late 2018, with topline results expected in 2023.

——from a press release May 18 2018

Dendreon has provided charitable support for Malecare programs in past years.

3 Replies

Thanks for this update Darryl---it went by me.



Has anyone enrolled in the Provent Trial for Provenge?


Not a fan.....Dendreon is really pushing because their patent is expiring. Provenge doesn't really work, and we were being directed towards a trial that could potentially have caused disease progression. It has been a disturbing experience to realize how much their funding of certain research hospital programs is affecting the advice oncologists are giving. your research.


You may also like...